Glenmark Therapeutics Inc, USA, has launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the United States. The product contains the same active ingredient as Differin® Gel, 0.1%, and expands Glenmark’s over-the-counter dermatology product portfolio. According to Nielsen syndicated data for the latest 52-week period ending September 5, 2026, the Differin® Gel, 0.1% over-the-counter market recorded annual sales of approximately US$45.8 million.
The new pump-pack format is designed to provide consumers with a convenient dispensing option for Adapalene Gel USP, 0.1%. The launch adds a new presentation to Glenmark’s existing US portfolio and is aimed at improving ease of use for consumers seeking over-the-counter dermatology products.
Commenting on the launch, Marc Kikuchi, President and Business Head, North America, Glenmark, said, “The introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio.” “This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs,” he added.
Adapalene Gel USP, 0.1% is an over-the-counter topical dermatology product. The availability of the product in a pump-pack format provides consumers with an alternative dispensing format as Glenmark expands its presence in the US consumer healthcare and dermatology market.
The launch is part of Glenmark’s broader strategy to build its portfolio across dermatology, respiratory care and other therapeutic areas. The company has a presence across branded, innovative, generic and consumer health products and operates commercial activities across more than 80 countries.
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company focused on innovation and access to medicines. Its therapeutic areas include respiratory, dermatology and oncology, supported by manufacturing and research infrastructure across multiple geographies. The company has 11 manufacturing facilities across four continents and six research and development centres. Its commercial footprint extends to more than 80 countries.
Glenmark’s portfolio includes branded and innovative medicines, generics and consumer healthcare products. The company has continued to expand its presence in the US market through product launches across its key therapeutic and consumer health segments.